Search the collection

414 results for Deucravacitinib

Sort by:

Sort by

Limit results to:

20 per page

414 results for Deucravacitinib

Export to excel

Export record to excel

File type to download

Beta version

Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 1
ArticlesPeer ReviewedFull Text
Deucravacitinib: First Approval: Deucravacitinib: First Approval
Author / Creator:Hoy, Sheridan M.
Publisher:Cham: Springer International Publishing
Journal title:Drugs (New York, N.Y.), 2022-11, Vol.82 (17), p.1671-1679
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 2
ArticlesPeer ReviewedFull Text
Deucravacitinib for the Treatment of Psoriatic Disease
Author / Creator:Lé, Ana Maria ; Puig, Luis ; Torres, Tiago
Publisher:Auckland: Springer Nature B.V
Journal title:American journal of clinical dermatology, 2022-11, Vol.23 (6), p.813-822
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 3
ArticlesPeer ReviewedFull Text
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
Author / Creator:Mease, Philip J ; Deodhar, Atul A ; van der Heijde, Désirée ; Behrens, Frank ; Kivitz, Alan J ; Neal, Jeffrey ; Kim, Jonghyeon ; Singhal, Shalabh ; Nowak, Miroslawa ; Banerjee, Subhashis
Publisher:England: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title:Annals of the rheumatic diseases, 2022-06, Vol.81 (6), p.815-822
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 4
ArticlesPeer ReviewedFull Text
Deucravacitinib for the Treatment of Psoriatic Disease: Deucravacitinib for Psoriatic Disease
Author / Creator:Lé, Ana Maria ; Puig, Luis ; Torres, Tiago
Publisher:Cham: Springer International Publishing
Journal title:American journal of clinical dermatology, 2022-11, Vol.23 (6), p.813-822
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 5
ArticlesPeer ReviewedFull Text
Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis
Author / Creator:Hu, Caixia ; Han, Xiaomei ; Cui, Yu ; Zhang, Yan ; Cheng, Yi
Publisher:England: John Wiley & Sons, Inc
Journal title:Skin research and technology, 2024-08, Vol.30 (8), p.e13855-n/a
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 6
ArticlesPeer ReviewedFull Text
First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
Author / Creator:Catlett, Ian M. ; Aras, Urvi ; Hansen, Lars ; Liu, Yali ; Bei, Di ; Girgis, Ihab G. ; Murthy, Bindu
Publisher:United States: John Wiley & Sons, Inc
Journal title:Clinical and translational science, 2023-01, Vol.16 (1), p.151-164
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 7
ArticlesPeer ReviewedFull Text
Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials
Author / Creator:Armstrong, April W. ; Kircik, Leon ; Stein Gold, Linda ; Strober, Bruce ; De Oliveira, Claudia H. M. C. ; Vaile, John ; Jou, Ying-Ming ; Daamen, Carolin ; Scharnitz, Thomas ; Lebwohl, Mark
Publisher:Cheshire: Springer Healthcare
Journal title:Dermatology and therapy, 2025-04, Vol.15 (4), p.1025-1035
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 8
ArticlesPeer ReviewedFull Text
AB1098 DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
Author / Creator:Korman, N. J. ; Passeron, T. ; Gordon, K. B. ; Okubo, Y. ; Bagel, J. ; Sofen, H. ; Warren, R. B. ; Bhatia, N. ; Spelman, L. ; Winthrop, K. ; Hippeli, L. ; Kisa, R. M. ; Banerjee, S. ; Thaçi, D.
Publisher:Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title:Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1774-1775
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 9
ArticlesPeer ReviewedFull Text
POS1536 ASSESSMENT OF PAIN OUTCOMES IN A PHASE 2 TRIAL OF DEUCRAVACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Author / Creator:Mease, P. J. ; Eder, L. ; Ogdie-Beatty, A. ; Deodhar, A. ; Banerjee, S. ; Nowak, M. ; Choi, J. ; Lehman, T. ; Strand, V.
Publisher:Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title:Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1132-1133
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 10
ArticlesPeer ReviewedFull Text
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Author / Creator:Chimalakonda, Anjaneya ; Burke, James ; Cheng, Lihong ; Catlett, Ian ; Tagen, Michael ; Zhao, Qihong ; Patel, Aditya ; Shen, Jun ; Girgis, Ihab G. ; Banerjee, Subhashis ; Throup, John
Publisher:Cheshire: Springer Healthcare
Journal title:Dermatology and therapy, 2021-10, Vol.11 (5), p.1763-1776
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 11
ArticlesPeer ReviewedFull Text
Successful Psoriasis Management With Deucravacitinib After Guselkumab‐Associated Eosinophilic Pneumonia
Author / Creator:Lovell, Katie K. ; Feldman, Steven R.
Publisher:Wiley
Journal title:JEADV clinical practice, 2025-06, Vol.4 (2), p.529-531
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 12
ArticlesPeer ReviewedFull Text
AB1374 DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS
Author / Creator:Strober, B. ; Sofen, H. ; Imafuku, S. ; Paul, C. ; Gooderham, M. ; Spelman, L. ; Seo, S. J. ; Passeron, T. ; Kisa, R. M. ; Berger, V. ; Vritzali, E. ; Hoyt, K. ; Colombo, M. J. ; Banerjee, S. ; Augustin, M. ; Stein Gold, L. ; Alexis, A. ; Thaçi, D. ; Blauvelt, A. ; Lebwohl, M.
Publisher:Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title:Annals of the rheumatic diseases, 2024-06, Vol.83 (Suppl 1), p.2039-2040
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 13
ArticlesPeer ReviewedFull Text
AB0515 PHARMACOKINETICS, SELECTIVITY PROFILE, AND EXPOSURE-RESPONSE RELATIONSHIP FOR EFFICACY AND SAFETY IN A PHASE 2 STUDY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIEN...
Author / Creator:Ide, T. ; Chiney, M. ; Bach, H. Y. T. ; Goti, V. ; Murthy, B. ; Hobar, C. ; Zhao, Q. ; Aras, U.
Publisher:Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title:Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1452-1453
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 14
ArticlesPeer ReviewedFull Text
AB1086 COVID-19–RELATED ADVERSE EVENTS IN THE PHASE 3 POETYK TRIALS OF THE ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, DEUCRAVACITINIB, IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Author / Creator:Thaçi, D. ; Gordon, K. B. ; Gooderham, M. ; Alexis, A. ; Lalchandani, V. ; Scotto, J. ; Hippeli, L. ; Colombo, M. J. ; Banerjee, S. ; Lezhava, T. ; Lebwohl, M.
Publisher:Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title:Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1764-1765
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 15
ArticlesPeer ReviewedFull Text
POS0112 DEUCRAVACITINIB REDUCES INTERFERONS, B-CELL PATHWAYS, AND SEROLOGICAL BIOMARKERS OF SYSTEMIC LUPUS DISEASE ACTIVITY: PHARMACODYNAMIC ANALYSIS FROM THE PHASE 2 PAISLEY STUDY
Author / Creator:Kahlenberg, J. M. ; Sanz, I. ; Wu, C. ; Hu, Y. ; Kim, J. H. ; Singhal, S. ; Catlett, I. M.
Publisher:Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title:Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.271-271
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 16
ArticlesPeer ReviewedFull Text
AB0521 IDENTIFICATION OF AN INTERFERON 5-GENE SIGNATURE SCORE AS A PHARMACODYNAMIC AND POTENTIAL PREDICTIVE BIOMARKER FOR DEUCRAVACITINIB TREATMENT IN A PHASE 2 TRIAL IN PATIENTS WITH SYSTEMIC LUPUS E...
Author / Creator:Wu, C. ; Hu, Y. ; Crow, M. K. ; Saxena, A. ; Arriens, C. ; Hobar, C. ; Coles, A. ; Catlett, I. M.
Publisher:Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title:Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1456-1456
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 17
ArticlesPeer ReviewedFull Text
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials
Author / Creator:Merola, Joseph F. ; Ferris, Laura K. ; Sobell, Jeffrey M. ; Sofen, Howard ; Osborne, John ; Vaile, John ; Jou, Ying-Ming ; Daamen, Carolin ; Scotto, Julie ; Scharnitz, Thomas ; Lebwohl, Mark
Publisher:Cheshire: Springer Healthcare
Journal title:Dermatology and therapy, 2025-02, Vol.15 (2), p.453-462
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 18
ArticlesPeer ReviewedFull Text
AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPU...
Author / Creator:Arriens, C. ; Askanase, A. ; Furie, R. ; Morand, E. F. ; Van Vollenhoven, R. ; Connors, K. ; Davey, M. ; Delev, N. ; Shah, V. ; Stevens, A. ; Wegman, T. ; Hobar, C.
Publisher:Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title:Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1463-1463
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 19
ArticlesPeer ReviewedFull Text
POS1550 IMPACT OF ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2 TRIAL
Author / Creator:Gottlieb, A. B. ; Armstrong, A. ; Merola, J. F. ; Napoli, A. ; Nowak, M. ; Banerjee, S. ; Lehman, T. ; Mease, P. J.
Publisher:Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title:Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1145-1146
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 20
ArticlesPeer ReviewedFull Text
Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System
Author / Creator:Zhao, Kaidi ; Xiao, Shengxiang ; Zhao, Yang ; Tu, Chen
Publisher:Netherlands
Journal title:International journal of clinical pharmacy, 2025-04
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.

Showing 1 to 20 of 414 results

Export record to excel

Export this record

Export record to excel

Deucravacitinib: First Approval: Deucravacitinib: First Approval

Export this record

Export record to excel

Deucravacitinib for the Treatment of Psoriatic Disease

Export this record

Export record to excel

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

Export this record

Export record to excel

Deucravacitinib for the Treatment of Psoriatic Disease: Deucravacitinib for Psoriatic Disease

Export this record

Export record to excel

Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis

Export this record

Export record to excel

First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2

Export this record

Export record to excel

Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials

Export this record

Export record to excel

AB1098 DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM

Export this record

Export record to excel

POS1536 ASSESSMENT OF PAIN OUTCOMES IN A PHASE 2 TRIAL OF DEUCRAVACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Export this record

Export record to excel

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

Export this record

Export record to excel

Successful Psoriasis Management With Deucravacitinib After Guselkumab‐Associated Eosinophilic Pneumonia

Export this record

Export record to excel

AB1374 DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS

Export this record

Export record to excel

AB0515 PHARMACOKINETICS, SELECTIVITY PROFILE, AND EXPOSURE-RESPONSE RELATIONSHIP FOR EFFICACY AND SAFETY IN A PHASE 2 STUDY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIEN...

Export this record

Export record to excel

AB1086 COVID-19–RELATED ADVERSE EVENTS IN THE PHASE 3 POETYK TRIALS OF THE ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, DEUCRAVACITINIB, IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Export this record

Export record to excel

POS0112 DEUCRAVACITINIB REDUCES INTERFERONS, B-CELL PATHWAYS, AND SEROLOGICAL BIOMARKERS OF SYSTEMIC LUPUS DISEASE ACTIVITY: PHARMACODYNAMIC ANALYSIS FROM THE PHASE 2 PAISLEY STUDY

Export this record

Export record to excel

AB0521 IDENTIFICATION OF AN INTERFERON 5-GENE SIGNATURE SCORE AS A PHARMACODYNAMIC AND POTENTIAL PREDICTIVE BIOMARKER FOR DEUCRAVACITINIB TREATMENT IN A PHASE 2 TRIAL IN PATIENTS WITH SYSTEMIC LUPUS E...

Export this record

Export record to excel

Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials

Export this record

Export record to excel

AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPU...

Export this record

Export record to excel

POS1550 IMPACT OF ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2 TRIAL

Export this record

Export record to excel

Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System

Refine your search